Transfusion of cryopreserved HPCs carries a risk of serious adverse effects due to the use of DMSO. Some studies have shown that the incidence and severity of adverse reactions are dose related. 1 It is desirable therefore to reduce the amount of DMSO in cryopreserved components to minimize toxicity, particularly in children.The concentration of DMSO and the concentration of cells to be cryopreserved determine the volume and the amount of DMSO infused. Previous studies 2,3 describe satisfactory results using 5-percent DMSO or 3.5percent DMSO with HES. Also, high cell concentrations (up to 800 ן 10 6 /mL) in 10-percent DMSO have not shown a deleterious impact on function or engraftment of HPCs, either in vitro or in vivo. 4 Our approach used a high cell concentration (>200 ן 10 6 /mL) and a low DMSO concentration (5 percent) for cryopreservation. We report hematologic recovery in patients who received such transplants.HPCs were collected from 13 consecutive patients for autologous transplant. The cells were cryopreserved with 5-percent DMSO in autologous plasma as the only cryoprotectant at a final cell concentration equal to or greater than 200 ן 10 6 per mL. The cells were frozen at -80ЊC by immersion in a methanol bath in a mechanical freezer, 5 and stored at that same temperature. All patients were conditioned with myeloablative regimens and medicated with corticosteroids, antihistamines, and diuretics prior to transfusion of their thawed, unmanipulated HPCs.There were 6 boys and 7 girls with a median age of 11.8 years (range 4.5-19.2). Diagnoses were brain tumor in 5, Ewing sarcoma in 3, Hodgkin disease in 2, neuroblastoma in 1, T-cell acute lymphoblastic leukemia in 1, and Burkitt lymphoma in 1.The median volume of the cryopreserved HPCs and their cell concentrations were 300 mL (range, 134-700) and 263 ן 10 6 per mL (range, 192-390), respectively, with a median CD34+ cell content of 3.66 ן 10 6 per kg (range, 2.00-6.44). Median time from cryopreservation to transplantation was 10 days (range, 9-108).The median dose of DMSO infused was 0.41 mL per kg (range, 0.13-0.58) in an HPC component with a median volume of 8.2 mL per kg (range, 2.7-11.7). Adverse effects during transfusion were minimal. One patient experienced abdominal pain and vomiting and another required treatment for hypertension with nifidipine. If the HPCs had been cryopreserved by standard protocols (cell concentration 100 ן 10 6/ mL in 10 percent DMSO), the median volume of DMSO and HPC component transfused would have been 1.8 mL per kg (range 0.70-4.55) and 18 mL per kg (range 7-45), respectively.A granulocyte count > 0.5 ן 10 9 per L and a platelet count > 20 ן 10 9 per L were achieved after a median of 11 (range 10-14) and 12 (range 10-23) days, respectively. Hematologic recovery was adequate (Hb > 100 g/L, platelets > 100 ן 10 9/ L, and granulocytes > 1 ן 10 9/ L) in 9 of 12 evaluable patients at 3 months and in 9 of 10 evaluable patients at 6 months post-transplant. The only patient not achieving the target values was ...